Literature DB >> 9577945

Reversal of abnormal coronary vasomotion by calcium antagonists in patients with hypercholesterolemia.

P A Kaufmann1, J Frielingsdorf, L Mandinov, C Seiler, R Hug, O M Hess.   

Abstract

BACKGROUND: It has been shown that exercise-induced coronary vasodilation of angiographically normal coronary vessels is reduced in hypercholesterolemic patients. The purpose of this study was to evaluate the effect of calcium channel blockers on coronary vasomotion of angiographically smooth coronary arteries in hypercholesterolemic patients. METHODS AND
RESULTS: A total of 57 patients were included in the present analysis. Vasomotion of angiographically normal coronary arteries was evaluated in 37 control subjects (group 1) without and 20 patients (group 2) with calcium blocker administration before physical exercise. Both groups were subdivided into subgroup A (normal cholesterol values: < or = 5.5 mmol/L or 212 mg%) and subgroup B (elevated cholesterol values: >5.5 mmol/L or 212 mg%). Coronary luminal area at rest and during exercise was assessed by biplane quantitative coronary angiography. The normal vessels showed a significant increase in coronary luminal area during exercise in subgroup A (n=13) with normal cholesterol values (31%; P<.05) but not in subgroup B (n=24; 13%; P=NS). In contrast, all patients in group 2 showed similar vasodilation during exercise, namely, 22% (P<.05) in subgroups A (n=8) and B (n=12) (P<.05). Independent of the actual cholesterol level, the stenotic lesions showed coronary vasoconstriction during exercise in group 1 but vasodilation in group 2 after pretreatment with calcium antagonists.
CONCLUSIONS: Coronary vasomotor response to exercise is inversely related to actual serum cholesterol level in angiographically normal vessels. Administration of calcium antagonists normalizes exercise-induced vasodilation and thus eliminates cholesterol-induced abnormal vasomotion, probably by a direct effect on the smooth muscles of the vasculature.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9577945     DOI: 10.1161/01.cir.97.14.1348

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

1.  Improvement of endothelial dysfunction as a surrogate endpoint in the treatment of hypertension.

Authors:  T Santoso
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

2.  PET-measured heterogeneity in longitudinal myocardial blood flow in response to sympathetic and pharmacologic stress as a non-invasive probe of epicardial vasomotor dysfunction.

Authors:  Thomas H Schindler; Alvaro D Facta; John O Prior; Roxana Campisi; Masayuki Inubushi; Michael C Kreissl; Xiao-Li Zhang; James Sayre; Magnus Dahlbom; Heinrich R Schelbert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-26       Impact factor: 9.236

3.  "Mismatch" in regional myocardial perfusion defects during exercise and pharmacologic vasodilation: a noninvasive marker of epicardial vasomotor dysfunction?

Authors:  Thomas H Schindler; Heinrich H Schelbert
Journal:  J Nucl Cardiol       Date:  2007 Nov-Dec       Impact factor: 5.952

4.  Myocardial flow reserve is influenced by both coronary artery stenosis severity and coronary risk factors in patients with suspected coronary artery disease.

Authors:  Takahiro Tsukamoto; Koichi Morita; Masanao Naya; Chietsugu Katoh; Masayuki Inubushi; Yuji Kuge; Hiroyuki Tsutsui; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-05-30       Impact factor: 9.236

5.  Increased myocardial blood flow during acute exposure to simulated altitudes.

Authors:  P A Kaufmann; C Schirlo; V Pavlicek; T Berthold; C Burger; G K von Schulthess; E A Koller; A Buck
Journal:  J Nucl Cardiol       Date:  2001 Mar-Apr       Impact factor: 5.952

Review 6.  The L-arginine-nitric oxide pathway in hypertension.

Authors:  Malte Kelm
Journal:  Curr Hypertens Rep       Date:  2003-02       Impact factor: 5.369

7.  Tetrahydrobiopterin restores impaired coronary microvascular dysfunction in hypercholesterolaemia.

Authors:  Christophe A Wyss; Pascal Koepfli; Mehdi Namdar; Patrick T Siegrist; Thomas F Luscher; Paolo G Camici; Philipp A Kaufmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-31       Impact factor: 9.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.